Sacubitril Valsartan Sodium Hydrate

DRUG2 trials

Sponsors

Saga University, Pachankis, Yang I., M.D.

Conditions

COVID-19 Vaccine Adverse ReactionHeart Failure

Phase 4

Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)

Active, not recruitingNCT05164653

Saga UniversityHeart Failure

Start: 2021-12-27End: 2025-03-31Target: 400Updated: 2024-08-21

Detoxification From the Lipid Tract

CompletedNCT06357104

Pachankis, Yang I., M.D.COVID-19 Vaccine Adverse Reaction

Start: 2024-02-26End: 2024-03-20Updated: 2024-04-10

Related Papers

Abstract 4357124: Echocardiographic Stratification of NT-proBNP Response to Sacubitril/Valsartan in Patients with Acute Heart Failure: A Sub-analysis of the PREMIER Trial

Circulation2025-11-03

Neuropathic Pains in the Age of Post-COVID-19-Vaccination

European Psychiatry2025-04-01

In-hospital initiation of angiotensin receptor–neprilysin inhibition in acute heart failure: the PREMIER trial

European Heart Journal2024-08-3120 citations